Home

About Us

Research

The Team

In the News

Contact Us

Home

Absynth was formed in 2007 from the University of Sheffield and is developing vaccines and antibodies to treat infections caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).

The company was founded using an initial investment of £325,000 from Biofusion plc (www.biofusion.co.uk) and is producing lead vaccine and therapeutic antibody candidates for entry into clinical trials. 

Hospital acquired infections are an increasing public health concern and are responsible for a rise in the number of hospital deaths.

These infections are caused by micro-organisms including MRSA. Absynth’s technology will be used to develop an MSRA vaccine and antibodies to treat significant MRSA infections as well as in other applications.

For further information, please browse this website or e-mail us at

 
 

Site Map